89. リンパ脈管筋腫症 Lymphangioleiomyomatosis Clinical trials / Disease details

臨床試験数 : 38 / 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118

diseases per page:

Showing 1 to 10 of 38 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000702-29-ES (EUCTR)	07/06/2021	09/02/2021	Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).	Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on ...	EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS MedDRA version: 21.0;Level: PT;Classification code ...	Trade Name: Loratadina STADA 10 mg Product Name: Loratadina Stada INN or Proposed INN: LORATADINE Other de ...	IDIBELL (Institut d’Investigació Biomédica de Bellvitge)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	62	Phase 2	Spain
2	NCT04388371 (ClinicalTrials.gov)	October 18, 2019	11/5/2020	Glutamine PET Imaging in LAM	Glutamine PET Imaging in LAM	Lymphangioleiomyomatosis (LAM)	Drug: Glutamine	Vanderbilt University Medical Center	The LAM Foundation	Completed	18 Years	N/A	Female	5	Phase 1	United States
3	NCT04273334 (ClinicalTrials.gov)	October 1, 2019	15/2/2020	Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders	Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Includin ...	Lymphatic Disorders	Drug: 68Ga-NEB	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	90	Phase 1	China
4	NCT03253913 (ClinicalTrials.gov)	March 31, 2018	10/8/2017	Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial	Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)	Lymphangioleiomyomatosis	Drug: Sirolimus;Drug: Resveratrol	University of Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	18 Years	N/A	Female	25	Phase 2	United States
5	NCT03131999 (ClinicalTrials.gov)	January 23, 2018	24/4/2017	LAM Pilot Study With Imatinib Mesylate	LAM Pilot Study With Imatinib Mesylate	Lymphangioleiomyomatosis	Drug: Imatinib Mesylate 400Mg Capsule;Drug: Placebo - Capsule	Medical University of South Carolina	Columbia University	Completed	18 Years	N/A	All	18	Phase 1/Phase 2	United States
6	NCT03150914 (ClinicalTrials.gov)	January 1, 2018	10/5/2017	Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial	Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial	LAM;Lymphangioleiomyomatosis	Drug: Sirolimus	University of Cincinnati	National Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Scienc ...	Recruiting	18 Years	N/A	Female	60	Phase 3	United States
7	NCT03062943 (ClinicalTrials.gov)	December 6, 2016	7/10/2016	A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)	A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)	Lymphangioleiomyomatosis	Drug: Nintedanib	IRCCS Multimedica	NULL	Completed	18 Years	N/A	Female	30	Phase 2	Italy
8	NCT02484664 (ClinicalTrials.gov)	June 15, 2016	25/6/2015	COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC	COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC	Lymphangioleiomyomatosis (LAM)	Drug: Celecoxib	Brigham and Women's Hospital	National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	70 Years	Female	12	Phase 2	United States
9	NCT02737202 (ClinicalTrials.gov)	April 2016	31/3/2016	Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis	Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis	Pulmonary Lymphangioleiomyomatosis	Drug: saracatinib	Baylor College of Medicine	University of Cincinnati;Brigham and Women's Hospital;Stanford University;Loyola University;Universi ...	Terminated	18 Years	65 Years	Female	28	Phase 2	United States
10	EUCTR2015-004919-20-IT (EUCTR)	09/03/2016	11/08/2016	A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)	A pilot study of nintedanib for lymphangioleiomyomatosis(LAM) - A pilot study of nintedanib for lymp ...	Female subjects affected by Llymphangioleiomyomatosis (LAM) MedDRA version: 19.0;Level: PT;Classific ...	Trade Name: Ofev	MULTIMEDICA S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	30	Phase 3	Italy

First Previous1 2 3 4Next Last